Immune thrombocytopenia due to olaparib
10.3760/cma.j.cn114015-20220215-00124
- VernacularTitle:奥拉帕利致免疫性血小板减少症
- Author:
Meng YUAN
1
;
Chunyan YANG
;
Yuanzhu WU
;
Mingqi YE
;
Jiajie LUAN
Author Information
1. 皖南医学院药学院，芜湖 241002
- Publication Type:Journal Article
- Keywords:
Thrombocytopenia;
Ovarian neoplasms;
Olaparib
- From:
Adverse Drug Reactions Journal
2022;24(10):549-551
- CountryChina
- Language:Chinese
-
Abstract:
A 69-year-old female patient received olaparide 300 mg orally twice daily after 6 cycles of chemotherapy with albumin paclitaxel+carboplatin regimen after cytoreductive surgery for ovarian cancer. The platelet count (PLT) was 151×10 9/L before the olaparide treatment, and on the 14th day of medication, her platelet count (PLT) was 17×10 9/L and platelet-associated immunoglobulin was positive. Immune thrombocytopenia due to olaparib was considered. The patient did not take the drug again. Thrombopoietin, eltrombopag, methylprednisolone, and platelet transfusion were given successively, but the PLT in the patients increased and decreased repeatedly, with the highest being 67×10 9/L, minimum 4×10 9/L.
